Personalized Approach to Promote Healthy Aging
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Arizona State University
- Enrollment
- 25
- Locations
- 3
- Primary Endpoint
- VO2 max
Study Overview
Brief Summary
The goal of this clinical trial study is to evaluate the impact of a personalized lifestyle intervention on improving healthspan. The primary questions of interest are whether the personalized intervention will result in improvements in muscle function, immune function, and cognitive function in adults aged 50-85 years. Participants will complete baseline assessments, receive an individualized intervention plan for approximately 3 months, and then complete post-intervention assessments. The intervention includes an exercise plan, nutrition recommendations, and general lifestyle goals that will be personalized to each participant.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 50 Years to 85 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •50-85 years of age
- •Non-smoking
- •Ambulatory without the need of an assistive device (walker, cane, etc.) and able to perform exercise testing and exercise training
- •English speaking
- •Owns a smart phone
Exclusion Criteria
- •Minors and adults younger than age 50 years and older than 85 years
- •Pregnant women
- •Adults who are unable to provide informed consent
- •Prisoners
Arms & Interventions
Lifestyle Intervention
All participants will receive an intervention.
Intervention: Lifestyle Management (Behavioral)
Outcomes
Primary Outcomes
VO2 max
Time Frame: From baseline to the end of the intervention at 3 months.
A maximal treadmill exercise test with respiratory gas exchange analysis to assess cardiorespiratory fitness.
Biodex
Time Frame: From baseline to the end of the intervention at 3 months.
A Biodex will be used to assess leg muscle power and strength.
Secondary Outcomes
- World Health Organization Quality of Life Survey(From baseline to the end of the intervention at 3 months.)
- Pittsburgh Sleep Quality Index(From baseline to the end of the intervention at 3 months.)
- Handgrip strength(From baseline to the end of the intervention at 3 months.)
- Dual Energy X-ray Absorptiometry (DXA)(From baseline to the end of the intervention at 3 months.)
- Waist circumference(From baseline to the end of the intervention at 3 months.)
- Hip circumference(From baseline to the end of the intervention at 3 months.)
- Systolic blood pressure(From baseline to the end of the intervention at 3 months.)
- Diastolic blood pressure(From baseline to the end of the intervention at 3 months.)
- Digit Symbol Substitution Test (DSST)(From baseline to the end of the intervention at 3 months.)
- Montreal Cognitive Assessment (MoCA)(From baseline to the end of the intervention at 3 months.)
- Short Physical Performance Battery(From baseline to the end of the intervention at 3 months.)
- Low Density Lipoprotein Cholesterol(From baseline to the end of the intervention at 3 months.)
- Hemoglobin A1C Concentration(From baseline to the end of the intervention at 3 months.)
- Insulin Concentration(From baseline to the end of the intervention at 3 months.)
- Geriatric Depression Scale (GDS)(From baseline to the end of the intervention at 3 months.)
- Generalized Anxiety Disorder (GAD)-7(From baseline to the end of the intervention at 3 months.)
- Perceived Stress Scale(From baseline to the end of the intervention at 3 months.)
- High Density Lipoprotein Cholesterol(From baseline to the end of the intervention at 3 months.)
- Brief Resilience Scale(From baseline to the end of the intervention at 3 months.)
- Non-High Density Lipoprotein Cholesterol(From baseline to the end of the intervention at 3 months.)
- Very Low Density Lipoprotein Cholesterol(From baseline to the end of the intervention at 3 months.)
- CD3 T cells(From baseline to the end of the intervention at 3 months.)
- CD4 T cells(From baseline to the end of the intervention at 3 months.)
- CD8 T cells(From baseline to the end of the intervention at 3 months.)
- Natural Killer cells(From baseline to the end of the intervention at 3 months.)
- B cells(From baseline to the end of the intervention at 3 months.)
Investigators
Susan Racette
Professor
Arizona State University